- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Keeshia Muhammad, Teva Specialty Pharmaceuticals
Keeshia Muhammad
Keeshia Muhammad
Executive Director, Marketing, Teva Specialty Pharmaceuticals
MAKES PHARMA A BETTER PLACE: The Healthcare Businesswomen's Association
REWARD: Standing ovations for marketing teams from the sales force
Keeshia Muhammad says much of what you need to know about co-promotion you learned in kindergarten. "It's about collaborating with people, with the foundation of integrity, trust, and respect. Hidden agendas ultimately tarnish relationships as you start to build a team."
Keeshia Muhammad
And she should know. Muhammad worked on the Merck/Schering-Plough joint venture for Zetia and Vytorin, maintained Altana's voice in its COPD hopeful PDE-4 inhibitor partnership with Pfizer, and managed Altana's co-promotion of Alvesco with Sanofi-Aventis. While she may have played nice in the past, Muhammad is showing an edge in her new role. Under her leadership, Teva's flagship asthma brand ProAir HFA has nearly doubled its market share to 60 percent. So how does she do it? "I bring passion and energy to the table," she says. "I always have people asking me, 'Can I have a dose of that?'"
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
